• News

"Mount Sinai Patient, Clinical Researcher Discuss New Treatment for Eczema Approved by FDA"

  • Mount Sinai Inside
  • (March 28, 2017)

An eczema patient in a Mount Sinai clinical trial and a Mount Sinai physician-scientist who led the trial discuss Dupixent® (dupilumab), the first biologic medicine approved by the U.S. Food and Drug Administration for the treatment of adults with moderate to severe atopic dermatitis. Learn more